A Focus on Long-Term Follow-Up of Immunoprophylaxis to Recurrent Urinary Tract Infections: 10 Years of Experience with MV140 Vaccine in a Cohort of 1003 Patients Support High Efficacy and Safety
-
Cristóbal Ramírez Sevilla [2] ; Esther Gómez Lanza [3] ; Juan Llopis Manzanera [1] ; Alfredo Cetina Herrando [2] ; Josep Miquel Puyol Pallàs [2]
-
[1] Hospital de Mataró
Hospital de Mataró
Barcelona, España
-
[2] Urology Deparment, Hospital Sant Joan de Déu de Martorell, Barcelona
-
[3] Urology Department, Hospital Moisés Broggi, Barcelona
-
- Localización: Archivos españoles de urología, ISSN 0004-0614, Tomo 75, Nº. 9, 2022, págs. 753-757
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Background: The objective of this article was to assess the long-term efficacy and safety of the MV140 vaccine to prevent recurrent urinary tract infections (UTIs).
Methods: This is a prospective, descriptive, comparative and multicenter study of 1003 patients with 3 or more urinary infections for 12 months, treated with the MV140 vaccine from 2011 to 2021. Variables: Age, gender, urinary infections at 3, 6 and 12 months, distribution according to age and months of the year, smoking, use of MV140 vaccines and autovaccines.
Results: Mean age was 78 and 82.7% were women. At baseline, 84.1% had 3 to 5 infections. According to age, 68.6% had >70 years. There were more consultations in March (12.3%) and fewer in August (4.4%). Smokers represented 24.6% and 21.8% follow autovaccines. Results at 3 months: 0 UTI 45%, 1 UTI 31.3%, 2 UTI 19.2%. 6 months: 0 UTI 29.3%, 1 UTI 33.2%, 2 UTI 24.3%. 12 months: 0 UTI 9%, 1 UTI 28.2%, 2 UTI 17.5%. Smokers: 0–1 UTI 80.2% (3 months), 65.5% (6 months), 53.9% (12 months). Non-smokers: 0–1 UTI 85.8% (3 months), 66.8% (6 months), 20% (12 months). p = 0.41, 0.27 and 0.21 respectively. Vaccines: 0–1 UTI 74.5% (3 months), 61% (6 months), 38.8% (12 months). Autovaccines: 0–1 UTI 82.7% (3 months), 68 % (6 months), 28.2% (12 months). p = 0.04, 0.25 and 0.63 respectively.
Conclusions: MV140 reduced the number of UTI to 0–2 in 95.5% at 3 months, 86.8% at 6 months and 54.7% at 12 months. Smoking did not worsen the response of MV140. Autovaccines achieved better results than vaccines only at 3 months. Adverse effects represented 1.49%, but no patient had to abandon treatment.
